With that, let's consider two dividend-paying companies that look like strong buys for the next two decades: Medtronic ( MDT -0.19%) and Merck ( MRK 3.72%).

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Merck & Co., Inc. (MRK) is currently at $82.84, up $3.00 or 3.76% --Would be highest close since April 3, 2025, when it closed at $86.39 --On pace for largest percent increase since March 27, 2024, ...

A modified FLOT regimen (fluorouracil, oxaliplatin, and docetaxel; TFOX) outperformed a standard chemotherapy triplet for the ...

Major stock indexes held firm in the stock market today after three days of bullish gains. Tesla spiked 9% and Nvidia led the ...

Merck, known as MSD outside the US and Canada, got approval for Vaxneuvance from the FDA in July – a month after Pfizer upped the ante in the competitive stakes with a green light for Prevnar-20 ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.